- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06221748
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
A Randomized,Multicenter, Open-Label,Phase II/III Study to Evaluate the Safety and Efficacy of Disitamab Vedotin Combined With Cadonilimab in Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma Who Have Progressed on r First-line Therapy
Study Overview
Status
Intervention / Treatment
Detailed Description
This is an open-label, randomized, multicenter, Phase II/III Study designed to evaluate safety and efficacy of Disitamab Vedotin Combined with Cadonilimab in subjects with HER2-expressing locally advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma after progression on first-line therapy.
This clinical study was divided into two parts, phase II and III.Part I: Phase II study primary objectives of the study are to evaluate the efficacy and safety of Disitamab Vedotin Combined with Cadonilimab versus Disitamab Vedotin versus paclitaxel in subjects with HER2-expressing locally advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma after progression on first-line therapy.
Part II: Phase III study primary objectives of the study are to evaluate the efficacy and safety of Disitamab Vedotin Combined with Cadonilimab versus paclitaxel in subjects with HER2-expressing locally advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma after progression on first-line therapy.
Tumor assessments, including radiological assessments by CT/MRI scans will be performed at Screening and subsequently every 6 weeks (±7 days) until disease progression, death, the start of new anticancer therapy, or patient's withdrawal of consent (whichever occurs first).
All patients who discontinue treatment will be followed for survival every 3 months until death, lost to follow-up, withdrawal of consent for survival follow-up, or end of study (whichever comes first).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Jianmin Fang, Ph.D
- Phone Number: +8610-58075763
- Email: Jianminfang@hotmail.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Recruiting
- Beijing Cancer Hospital
-
Principal Investigator:
- Lin Shen, M.D
-
Contact:
- Lin Shen, M.D.
-
-
Fujian
-
Xiamen, Fujian, China, 361003
- Not yet recruiting
- The First Affiliated Hospital of Xiamen University
-
Contact:
- Feng Ye, M.D
-
-
Heilongjiang
-
Ha'erbin, Heilongjiang, China, 150081
- Not yet recruiting
- Harbin Medical University Cancer Hospital
-
Contact:
- Yanqiao Zhang, M.D
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- Not yet recruiting
- The First Affiliated Hospital of Zhengzhou University
-
Contact:
- Yanru Qin, M.D
-
-
Hubei
-
Wuhan, Hubei, China, 430079
- Not yet recruiting
- Hubei Cancer Hospital
-
Contact:
- Huiting Xu, M.D
-
-
Hunan
-
Changsha, Hunan, China, 410031
- Recruiting
- Hunan Cancer Hospital
-
Contact:
- Zhenyang Liu, M.D
-
-
Jiangsu
-
Xuzhou, Jiangsu, China, 221009
- Recruiting
- Xuzhou Central Hospital
-
Contact:
- Yuan Yuan, M.D
-
-
Shandong
-
Jinan, Shandong, China, 250117
- Recruiting
- Shandong Cancer Hospital
-
Principal Investigator:
- Changzheng Li
-
Contact:
- Changzheng Li, M.D
-
Qingdao, Shandong, China, 266003
- Not yet recruiting
- The Affiliated Hospital of Qingdao University
-
Contact:
- Jing Lv, M.D
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Not yet recruiting
- Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
-
Contact:
- Jun Zhang, M.D
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Not yet recruiting
- West China Hospital of Sichuan University
-
Contact:
- Hongfeng Gou, M.D
-
-
Yunnan
-
Kunming, Yunnan, China, 650118
- Recruiting
- Yunnan Cancer Hospital
-
Contact:
- Lin Xie, M.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily agreed to participate in the study and signed an informed consent form;
- Age 18-75 years(both 18 and 75);
- Expected survival ≥ 12 weeks
- ECOG physical condition score of 0 or 1
- Locally advanced or metastatic gastric adenocarcinoma (including adenocarcinoma of the gastroesophageal junction) confirmed by histology and/or cytology
- Subjects will only have failed or been intolerant to prior standard first-line therapy (excluding paclitaxel), with no restriction on prior treatment with a PD-1/PD-L1 inhibitor.
- Confirmation of HER2 (IHC 1+, 2+, or 3+) and PD-L1 expression: for Phase II enrolled subjects, results of investigator-confirmed HER2 and PD-L1 expression will be accepted; for Phase III enrolled subjects, HER2 and PD-L1 expression will be accepted only as results from the central laboratory.
Bone marrow function:
- Hemoglobin ≥ 9 g/dL (no blood transfusion and no erythropoietin treatment within 2 weeks prior to the examination);
- Absolute neutrophil count ≥ 1.5 × 109/L (must not receive granulocyte colony-stimulating factor treatment within 2 weeks prior to the examination)
- Platelet count ≥ 90 × 109/L (no platelet transfusion or treatment with recombinant human thrombopoietin within 2 weeks before the test);
Liver function (based on normal values at the Clinical Trials Center):
- Serum total bilirubin ≤ 1.5 times the upper limit of normal (ULN);
- Alanine aminotransferase (ALT) and Mentholatum aminotransferase (AST) ≤ 2.5 × ULN in the absence of hepatic metastases; ALT and AST ≤ 5 × ULN in the presence of hepatic metastases;
Renal function (based on normal values at the Clinical Trials Center):
Blood creatinine ≤ 1.5 x ULN, or creatinine clearance (CrCl) ≥ 60 mL/min calculated by the Cockcroft-Gault formula method, or measured 24-hour urine CrCl ≥ 60 mL/min;
Coagulation:
- Prothrombin time (PT) ≤ 1.5 x ULN;
- Thrombin time (TT) ≤ 1.5 × ULN;
- Activated partial thromboplastin time (APTT) ≤ 1.5×ULN;
Cardiac function:
- New York Heart Association (NYHA) classification <3;
- Left ventricular ejection fraction (LVEF) ≥ 50%;
- The subject is able to provide specimens for central laboratory testing/review (at least 5 tissue sections) from the site of the primary or metastatic focus of the tumor within 3 years, preferably specimens taken after failure of first-line therapy;
- Have at least one measurable lesion according to RECISTv1.1 criteria;
- For female subjects: should be surgically sterilized, post-menopausal, or agree to use a medically approved contraceptive method (e.g., IUD, birth control pills, or condoms) for the duration of the study treatment and for 6 months after the end of the study treatment period; must have had a negative blood pregnancy test within 7 days prior to the study drug administration and must not be breastfeeding; and must not donate eggs for a period of 6 months from the time of signing of the informed consent form to the time of the last administration of the study drug. No egg donation for 6 months. For male subjects: should be surgically sterilized or agree to use a medically approved method of contraception during and for 6 months after the end of study treatment; no sperm donation from the time of signing the informed consent until at least 4 months after the last dose of study drug;
- Be able to understand the requirements of the trial and be willing and able to comply with the trial and follow-up procedures.
Exclusion Criteria:
- Metastatic CNS and/or meningeal carcinomatosis;
- prior treatment with any antibody-drug conjugate including Disitamab Vedotin For Injection; prior treatment with cardinolizumab
- Prior anti-cancer therapy resulting in toxicity that has not recovered to CTCAE (version 5.0) ≤ Grade 1 (except for hair loss, hyperpigmentation, or other conditions that do not increase the risk of the subject's use of the drug determined by the investigators;
- Radical radiotherapy within 3 months prior to study dosing; palliative radiotherapy 2 weeks prior to dosing is permitted, at a dose that meets local diagnostic criteria for palliative care and with radiotherapy coverage of less than 30% of the bone marrow area;
- Prior major surgery within 4 weeks before study dose start and incomplete recovery
- Received a live vaccine within 28 days prior to the start of the first study dose or plan to receive any vaccine during the study period
- Third interstitial effusion associated with clinical symptoms or that requires symptomatic treatment;
- Ongoing grade ≥2 sensorimotor or motoneuropathy;
serum virology (based on site normal values):
- Positive Hepatitis B virus surface antigen (HBsAg) test result with a positive HBV DNA copy number;
- Positive test result for Hepatitis C Antibody (HCVAb) (enrollment in the study is only possible if the PCR test result for HCV RNA is negative);
- Positive test result for human immunodeficiency virus antibody (HIVAb).;
- Serious arterial/venous or cardiovascular accidents, such as deep vein thrombosis ( except asymptomatic interstitial vein thrombosis which does not require special treatment), pulmonary embolism, cerebral infarction, cerebral hemorrhage, myocardial infarction, angina pectoris, etc., except for lacunar cerebral infarction, which is asymptomatic and does not require clinical intervention, have occurred in the last 6 months prior to the study drug administration;
- Tumor lesions with bleeding tendency (e.g., presence of active ulcerated tumor lesions with a positive fecal occult blood test, history of vomiting blood or black stools within 2 months prior to signing the informed consent form, risk of gastrointestinal hemorrhage in the judgment of the investigator, etc.), or receipt of blood transfusion 4 weeks prior to study drug administration;;
- The occurrence of an active or progressive infection requiring systemic treatment (trial drug may be initiated 2 weeks after completion of anti-infective therapy);
- The presence of unsteady controlled systemic disease as judged by the investigator, including diabetes and hypertension, hepatocirrhosis, interstitial pneumonitis, and obstructive lung disease.
- The existence of active autoimmune disease requiring systemic therapy (e.g., use of immunomodulatory agents, corticosteroids, or immunosuppressive agents) within 2 years prior to the start of study dosing, allowing for related replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for renal or pituitary insufficiency);
- Other malignancy within 5 years prior to the start of study dosing, with the exception of the following: malignancies that are expected to resolve with treatment (including, but not limited to, adequately treated thyroid cancer, carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated by radical surgery);
- prior history of allogeneic hematopoietic stem cell transplantation or organ transplantation;
- known hypersensitivity to immunosuppressants and any other antibody-drug conjugate and their components and any of the drugs in this study;
- women who are pregnant or breast-feeding;
- Any other disease, metabolic abnormality, physical examination abnormality, or laboratory test abnormality that, in the judgment of the Investigator, gives reason to suspect that the subject has a disease or condition that is unsuitable for the use of the study medication, would interfere with the interpretation of the results of the study, or puts the subject at a high risk of developing a condition;
- subjects whose participation in this study is estimated to be insufficiently adherent or who, in the judgment of the investigator, have other factors that make them unsuitable for participation in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Disitamab Vedotin + Cadonilimab
Disitamab Vedotin With Cadonilimab
|
Phase II and III study :2.5mg/kg, intravenous infusion,D1, every 2 weeks
Other Names:
Phase II and III study :6.0mg/kg, intravenous infusion,D1, every 2 weeks.
Other Names:
|
Experimental: Disitamab Vedotin
Disitamab Vedotin arm
|
Phase II and III study :2.5mg/kg, intravenous infusion,D1, every 2 weeks
Other Names:
|
Experimental: Paclitaxel
Paclitaxel Arm
|
Phase II and III study :Calculate dosage based on body surface are,160mg/m2,intravenous infusion,D1,D8 every 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective remission rate (ORR) (Phase II)
Time Frame: Up to approximately 2 years
|
ORR assessed according to the evaluation criteria for the efficacy of solid tumors (RECIST 1.1)
|
Up to approximately 2 years
|
Percentage of Participants With Adverse Events (AEs)(Phase II)
Time Frame: Up to approximately 2 years
|
Number of participants with adverse effects of treatment.
Frequency and severity of adverse effects of treatment as assessed by NCI CTCAE v5.0
|
Up to approximately 2 years
|
Progression-Free Survival(PFS) (IRC)( Phase III)
Time Frame: Up to approximately 2 years
|
PFS was defined as the time from random assignment to the onset of disease progression (as assessed by the IRC according to RECIST v1.1 criteria) or death (whichever event occurs first)
|
Up to approximately 2 years
|
Overall Survival (OS)(Phase III)
Time Frame: Up to approximately 2 years
|
OS was defined as the time from the date of randomization to the date of death from any cause.
|
Up to approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival(PFS)(investigator)(Phase II and Phase III)
Time Frame: Up to approximately 2 years
|
PFS was defined as the time from random assignment to the onset of disease progression (as assessed by the IRC according to RECIST v1.1 criteria) or death (whichever event occurs first)
|
Up to approximately 2 years
|
Overall Survival (OS)(Phase II)
Time Frame: Up to approximately 2 years
|
OS was defined as the time from the date of randomization to the date of death from any cause.
|
Up to approximately 2 years
|
Objective remission rate (ORR) (investigator) (Phase III)
Time Frame: Up to approximately 2 years
|
ORR assessed according to the evaluation criteria for the efficacy of solid tumors (RECIST 1.1)
|
Up to approximately 2 years
|
Disease Control Rate (DCR) (Phase II and Phase III)
Time Frame: Until progression, assessed up to approximately 2 years
|
Percentage of patients with complete response, partial response, or stable disease for a certain period of time according to RECIST v1.1.
|
Until progression, assessed up to approximately 2 years
|
Duration of response (DoR) (Phase II and Phase III)
Time Frame: Until progression, assessed up to approximately 2 years
|
Defined as the time from the date of first documented response (CR/PR) until the first progression or death in the absence of disease progression by Investigators assessment according to RECIST 1.1
|
Until progression, assessed up to approximately 2 years
|
Type, incidence, relatedness, severity, and seriousness of AEs
Time Frame: Up to approximately 2 years
|
According to NCI-CTCAE Version 5.0 per each treatment arm
|
Up to approximately 2 years
|
Incidence of laboratory tests abnormalities
Time Frame: Up to follow-up period, approximately 2 years
|
To be summarized using descriptive statistics
|
Up to follow-up period, approximately 2 years
|
Incidence of ECG abnormalities
Time Frame: Up to follow-up period, approximately 2 years
|
To be summarized using descriptive statistics
|
Up to follow-up period, approximately 2 years
|
Incidence of echocardiograms abnormalities
Time Frame: Up to approximately 2 years
|
Change from baseline of LVEF
|
Up to approximately 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jianmin Fang, Ph.D, RemeGen Co., Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Stomach Neoplasms
- Adenocarcinoma
- Esophageal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Immunoconjugates
- Paclitaxel
- Disitamab vedotin
Other Study ID Numbers
- RC48-C035
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on Disitamab Vedotin Injection
-
RemeGen Co., Ltd.Not yet recruitingHigh-risk Non-muscle Invasive Bladder CancerChina
-
Tianjin Medical University Second HospitalRecruitingHer2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial CarcinomaChina
-
RemeGen Co., Ltd.Not yet recruitingCastration-resistant Prostate CancerChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNanfang Hospital of Southern Medical University; The Third Affiliated Hospital... and other collaboratorsNot yet recruiting
-
Cancer Institute and Hospital, Chinese Academy...Shanxi Province Cancer HospitalRecruitingMuscle Invasive Bladder CarcinomaChina
-
RemeGen Co., Ltd.Recruiting
-
RemeGen Co., Ltd.Recruiting
-
Peking University Cancer Hospital & InstituteNot yet recruitingMetastatic Castration-resistant Prostate Cancer
-
Seagen Inc.RecruitingCarcinoma, Non-Small-Cell Lung | Ovarian Neoplasms | Endometrial Neoplasms | Carcinoma, Squamous Cell of Head and NeckUnited States, Australia, Canada